HC Wainwright Reaffirms Buy Rating for Sangamo Therapeutics (NASDAQ:SGMO)

HC Wainwright reissued their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO - Free Report) in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a $10.00 price target on the biopharmaceutical company's stock.

Other research analysts also recently issued research reports about the company. StockNews.com downgraded Sangamo Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, December 24th. Wells Fargo & Company reduced their price objective on Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research note on Tuesday. Jefferies Financial Group decreased their price objective on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating for the company in a report on Tuesday. Truist Financial raised shares of Sangamo Therapeutics from a "hold" rating to a "buy" rating and set a $7.00 target price on the stock in a report on Friday, December 13th. Finally, Barclays lifted their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an "overweight" rating in a report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $5.50.

Sangamo Therapeutics Price Performance

Shares of NASDAQ:SGMO traded up $0.11 during midday trading on Thursday, reaching $1.13. The company had a trading volume of 13,600,541 shares, compared to its average volume of 7,095,709. The stock has a market capitalization of $235.77 million, a P/E ratio of -1.51 and a beta of 1.15. The stock's fifty day moving average price is $2.14 and its 200-day moving average price is $1.22. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The company had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. During the same quarter in the previous year, the firm earned ($0.34) EPS. As a group, sell-side analysts forecast that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in Sangamo Therapeutics during the 3rd quarter valued at about $150,000. Geode Capital Management LLC raised its holdings in shares of Sangamo Therapeutics by 14.6% during the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company's stock valued at $1,853,000 after buying an additional 272,123 shares during the last quarter. XTX Topco Ltd boosted its position in shares of Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company's stock worth $90,000 after buying an additional 64,981 shares during the period. State Street Corp grew its holdings in Sangamo Therapeutics by 28.0% in the 3rd quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company's stock worth $576,000 after buying an additional 145,400 shares in the last quarter. Finally, FMR LLC increased its position in Sangamo Therapeutics by 16.5% in the 3rd quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company's stock valued at $471,000 after acquiring an additional 77,032 shares during the period. Institutional investors own 56.93% of the company's stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.